Determination of the risk of liver fibrosis with the FIB-4 scale in 290,353 spanish workers: Associated variables

María Teresa García-González; Ángel Arturo López González; Marta Pérez-Lema; María José Recatalá; Hector Eugercios; Rosa Buitrago-Leal

doi:10.5281/zenodo.14582894

Authors

María Teresa García-González Multiprofessional Teaching Unit of Occupational Health. Balearic Islands. Spain https://orcid.org/0009-0006-4709-7489
Ángel Arturo López González Multiprofessional Teaching Unit of Occupational Health, Balearic Islands, Spain
Marta Pérez-Lema Multiprofessional Teaching Unit of Occupational Health, Balearic Islands, Spain https://orcid.org/0000-0001-8577-8804
María José Recatalá Multiprofessional Teaching Unit of Occupational Health, Balearic Islands, Spain https://orcid.org/0000-0002-4155-5526
Hector Eugercios Multiprofessional Teaching Unit of Occupational Health, Balearic Islands, Spain https://orcid.org/0000-0002-8088-9609
Rosa Buitrago-Leal Multiprofessional Teaching Unit of Occupational Health, Balearic Islands, Spain https://orcid.org/0009-0008-5809-9900

DOI:

https://doi.org/10.5281/zenodo.14582894

Keywords:

FIB-4, hepatic fibrosis, obesity, socioeconomic status, tobacco consumption

Abstract

Objective: Liver fibrosis is a progressive disease characterised by the accumulation of excessive scar tissue in the liver. It occurs in response to chronic viral hepatitis, alcohol abuse or non-alcoholic fatty liver disease (NAFLD). There are different ways to diagnose it, including FIB-4. The aim of this study is to assess which variables are associated with increased liver fibrosis as determined by FIB-4.

Material and methods: A cross-sectional descriptive study of 290,353 Spanish workers, evaluating the influence of age, sex, social class, tobacco consumption, and BMI on the prevalence of hepatic fibrosis determined by FIB-4.

Results: The prevalence of moderate and high FIB-4 values is 12.8% in women and 4% in women. These prevalence increase with age, as socioeconomic status decreases, in smokers and as BMI increases.

Conclusion: The profile of a person with elevated FIB-4 values will be a male, older, with a low socioeconomic status, smoker and overweight.

References

Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209-18.

Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol. 2003;38(1):38-53.

Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med. 2006;10(1):76-99.

Pinzani M. Pathophysiology of liver fibrosis. Dig Dis. 2015;33(4):492-7.

Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838-51.

Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112-25.

Mello T, Ceni E, Surrenti C, Galli A. Alcohol induced hepatic fibrosis: role of acetaldehyde. Mol Aspects Med. 2008;29(1-2):17-21.

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of NAFLD. Hepatology. 2016;64(1):73-84.

Karlsen TH, Boberg KM. Update on primary sclerosing cholangitis. J Hepatol. 2013;59(3):571-82.

Brunt EM, Wong VW. Nonalcoholic fatty liver disease: what’s new under the sun. Clin Liver Dis (Hoboken). 2018;12(5):122-7.

Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology. 2009;49(3):1017-44.

Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835-47.

Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol. 2006;12(23):3682-94.

Toguchi M, Tsurusaki M, Yada N, Sofue K, Hyodo T, Onoda M, et al. Magnetic resonance elastography in the assessment of hepatic fibrosis: a study comparing transient elastography and histological data in the same patients. Abdom Radiol (NY). 2017;42(6):1659-66.

Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy. J Magn Reson Imaging. 2011;34(4):729-49.

Domingo-Salvany A, Bacigalupe A, Carrasco JM, Espelt A, Ferrando J, Borrell C, et al. Propuestas de clase social neoweberiana y neomarxista a partir de la Clasificación Nacional de Ocupaciones. Gac Sanit. 2013;27(3):263-72.

Kjaergaard M, Lindvig KP, Thorhauge KH, Andersen P, Hansen JK, Kastrup N, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol. 2023;79(2):277-86.

Shah AG, Smith PG, Sterling RK. Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. Dig Dis Sci. 2011;56(10):3038-44.

McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, et al. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. Am J Gastroenterol. 2017;112(5):740-51.

Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC Jr. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47(4):1363-70.

Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32-6.

European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol. 2014;60(2):392-420.

Marcellin P, Kutala BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018;38:2-6.

GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245-66.

Johnston MP, Patel J, Byrne CD. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD). Curr Pharm Des. 2020;26(10):1079-92.

Yang WJ, Kang D, Song MG, Seo TS, Kim JH. The Impact of Socioeconomic Status on Mortality in Patients with Hepatocellular Carcinoma: A Korean National Cohort Study. Gut Liver. 2022;16(6):976-84.

Zelber-Sagi S, Shoham D, Zvibel I, Abu-Abeid S, Shibolet O, Fishman S. Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients. World J Hepatol. 2017;9(2):91-8.

Marti-Aguado D, Clemente-Sanchez A, Bataller R. Cigarette smoking and liver diseases. J Hepatol. 2022;77(1):191-205.

Cheung K, Lee SS, Raman M. Prevalence and mechanisms of liver disease in individuals with obesity and type 2 diabetes. Curr Diabetes Rev. 2019;15(1):36-42.

Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, et al. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology. 2018;155(2):443-457.e17.

Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of nonalcoholic steatohepatitis. Prog Lipid Res. 2013;52(1):175-91.